UK's Allergy Therapeutics H1 revenue rises 7%, operating loss widens

Allergy Therapeutics

31/03/2026 07:15

Overview

UK allergy immunotherapy biotech's H1 revenue grew 7% yr/yr despite German product phase-out

Operating loss pre-R&D widened to £2.5 mln as investment in growth projects increased

Company secured new £40 mln senior loan facility post-period to fund future investment

Outlook

Company expects sales momentum in Germany to accelerate in H2 following Grassmuno launch

Allergy Therapeutics says it has sufficient funds for the next twelve months after £40 mln facility

Company continues to explore dual primary listing on Hong Kong Stock Exchange

Result Drivers

GERMAN PORTFOLIO - Co said H1 revenue growth was driven by strong performance in its German registered product portfolio despite phase-out of unregistered products

GRASSMUNO LAUNCH - Launch of Grassmuno in Germany contributed to commercial momentum, with strong response from prescribing clinicians

HIGHER COSTS - Increased sales, marketing, and administrative expenses mainly reflected investment in the Grassmuno launch and positioning for future growth

Company press release: ID:nRSe7099Ya

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
H1 Net Income
-GBP 19.92 mln
H1 EBIT
-GBP 11.38 mln
H1 Gross Profit
GBP 21.48 mln
H1 Pretax Profit
-GBP 19.33 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)